Kesar Petroprod. (524174)

Score breakdown: P/E: 2/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• ROE of 12.62% is respectable for a small commodity chemicals player.
• P/B of 1.33 with book value at ₹13.34 offers some asset backing, though price is above book.
• Latest quarter net profit of ₹3 Cr on ₹41 Cr sales implies a decent operating margin.
• Profit decline of only 0.68% despite a 17.40% sales drop suggests some cost flexibility.
• P/E of 13.81 is not excessive if earnings are near a cyclical trough.

Concerns

• Sales declined 17.40%, indicating weak demand or pricing pressure.
• Piotroski F-Score of 3/9 signals poor fundamental health.
• ROCE of 7.11% is low; the gap with ROE hints at possible leverage, and debt/equity is undisclosed.
• No dividend, and price is below the 52-week low of ₹20.00, reflecting negative market sentiment.

AI Analysis

I approach Kesar Petroprod with caution. This is a commodity chemical business, and commodity chemicals are price-takers. In the latest quarter, sales are ₹41 crore and net profit ₹3 crore; annualized, that is perhaps ₹12 crore against a ₹172 crore market cap, hence a P/E near 13.8. But the top line has shrunk 17.4% over the year. That decline is not the hallmark of a franchise with pricing power; it tells me the business is subject to cyclical forces. Benjamin Graham taught us to seek a margin of safety. At ₹17.79, the stock trades at 1.33 times book and slightly below its 52-week low of ₹20. Profit has fallen only marginally, but that may be driven by cost cuts or other income rather than operational strength. ROCE is just 7.11%, while ROE is 12.62%; the gap suggests the company is relying on leverage to juice equity returns. Since debt/equity is not provided, I cannot verify balance-sheet safety, and that is a red flag. The Piotroski F-score of 3 out of 9 reinforces my concern: the underlying financial health is weak. There is no dividend yield, so the patient investor gets no payment while waiting for a recovery. A commodity chemicals company with shrinking sales, mediocre return on capital, and no moat does not fit my circle of competence as a durable compounding machine. The book value of ₹13.34 gives some cushion, but paying ₹17.79 for that cushion requires a turnaround I cannot confirm from these numbers. I would put this in the cyclical basket. If the commodity cycle turns, earnings could recover, but I need evidence of stabilizing prices, better capacity utilization, and lower leverage. Until then, I would rather watch from the sidelines.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer